FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Davide Verotta

Research Profile

Physiology

Pharmacokinetics

Concepts & Ideas

Activities & Behaviors

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Adam Frymoyer; Pamala Jacobson; Davide Verotta; Janel Long-Boyle
Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.
Betty J Dong; Adam Frymoyer; Michael D Hughes; Patricia S Lizak; Shahin Lockman; Frederick Sawe; Davide Verotta; Yu Zheng; Francesca T Aweeka; Judith S Currier
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
Davide Verotta
Fractional dynamics pharmacokinetics-pharmacodynamic models.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Davide Verotta (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Adam Frymoyer; Pamala Jacobson; Davide Verotta; Janel Long-Boyle
Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.
British journal of clinical pharmacology 2013;75(2):463-75.
2012: Betty J Dong; Adam Frymoyer; Michael D Hughes; Patricia S Lizak; Shahin Lockman; Frederick Sawe; Davide Verotta; Yu Zheng; Francesca T Aweeka; Judith S Currier
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
AIDS (London, England) 2012;26(7):833-41.
2010: Davide Verotta
Fractional dynamics pharmacokinetics-pharmacodynamic models.
Journal of pharmacokinetics and pharmacodynamics 2010;37(3):257-76.
2010: Davide Verotta
Fractional compartmental models and multi-term Mittag-Leffler response functions.
Journal of pharmacokinetics and pharmacodynamics 2010;37(2):209-15; discussion 217-20.
2009: Janice B Schwartz; Davide Verotta
Population analyses of atorvastatin clearance in patients living in the community and in nursing homes.
Clinical pharmacology and therapeutics 2009;86(5):497-502.
2008: Smita Kshirsagar; Robert Gear; Jon Levine; Davide Verotta
A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain.
Journal of pharmacokinetics and pharmacodynamics 2008;35(1):69-83.
2007: Dongwoo Kang; Davide Verotta
Reversible jump Markov chain Monte Carlo for deconvolution.
Journal of pharmacokinetics and pharmacodynamics 2007;34(3):263-87.
2007: Smita A Kshirsagar; Terrence F Blaschke; Lewis B Sheiner; M Krygowski; Edward P Acosta; Davide Verotta
Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.
Journal of pharmacokinetics and pharmacodynamics 2007;34(1):35-55.
2006: Line Labbé; Davide Verotta
A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients.
Journal of pharmacokinetics and pharmacodynamics 2006;33(4):519-42.
2006: Chantal Csajka; Davide Verotta
Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
Journal of pharmacokinetics and pharmacodynamics 2006;33(3):227-79.
2006: Dongwoo Kang; Davide Verotta; Janice B Schwartz
Population analyses of amlodipine in patients living in the community and patients living in nursing homes.
Clinical pharmacology and therapeutics 2006;79(1):114-24.
2005: Dongwoo Kang; Janice B Schwartz; Davide Verotta
Sample size computations for PK/PD population models.
Journal of pharmacokinetics and pharmacodynamics 2005;32(5-6):685-701.
2005: Chantal Csajka; David R Drover; Davide Verotta
The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption.
Pharmaceutical research 2005;22(8):1227-35.
2005: Chantal Csajka; Bruno P Imbimbo; Annalisa Piccinno; Philippe Dostert; Davide Verotta
Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects.
The Journal of pharmacology and experimental therapeutics 2005;313(2):647-57.
2005: Marta Valle; Enrico Di Salle; Maria Gabriella Jannuzzo; Italo POggesi; Maurizio Rocchetti; Riccardo Spinelli; Davide Verotta
A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.
British journal of clinical pharmacology 2005;59(3):355-64.
2005: Chantal Csajka; Christine A Haller; Neal L Benowitz; Davide Verotta
Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects.
British journal of clinical pharmacology 2005;59(3):335-45.
2004: Dongwoo Kang; Janice B Schwartz; Davide Verotta
A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models.
Statistics in medicine 2004;23(16):2551-66.
2004: Marta Valle; Richard W Price; Annelie Nilsson; Melvyn Heyes; Davide Verotta
CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
Brain : a journal of neurology 2004;127(Pt 5):1047-60.
2003: Davide Verotta
Volterra series in pharmacokinetics and pharmacodynamics.
Journal of pharmacokinetics and pharmacodynamics 2003;30(5):337-62.
2003: Dongwoo Kang; Davide Verotta; Mary Ellen Krecic-Shepard; Nishit B Modi; Suneel K Gupta; Janice B Schwartz
Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.
Clinical pharmacology and therapeutics 2003;73(1):31-40.
2002: David R Drover; Martin S Angst; Marta Valle; Bhamini Ramaswamy; Sujata Naidu; Donald R Stanski; Davide Verotta
Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.
Anesthesiology 2002;97(4):827-36.
2002: Maria Pitsiu; Jean-Michel Gries; Neal L Benowitz; Steven G Gourlay; Davide Verotta
Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum.
Journal of pharmacokinetics and pharmacodynamics 2002;29(4):383-402.
2002: Davide Verotta; Franziska Schaedeli
Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials.
Mathematical biosciences 2002;176(2):163-83.
2002: Franziska Schaedeli; Maria Pitsiu; Neal L Benowitz; Steven G Gourlay; Davide Verotta
Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation.
Journal of pharmacokinetics and pharmacodynamics 2002;29(1):49-66.
2001: J Lu; Jean-Michel Gries; Davide Verotta; Lewis B Sheiner
Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.
Journal of pharmacokinetics and pharmacodynamics 2001;28(4):343-62.
2001: Maria Pitsiu; G Sathyan; S Gupta; Davide Verotta
A semiparametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin.
Journal of pharmaceutical sciences 2001;90(6):702-12.
2000: Jean-Michel Gries; Davide Verotta
Linear mixed-effect multivariate adaptive regression splines applied to nonlinear pharmacokinetics data.
Journal of biopharmaceutical statistics 2000;10(3):383-98.
2000: Christoph H Kindler; Davide Verotta; Andrew T Gray; Michael A Gropper; C Spencer Yost
Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium.
Anesthesiology 2000;92(3):821-32.
1999: Jean-Michel Gries; Alain Munafo; HC Porchet; Davide Verotta
Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin.
The Journal of pharmacology and experimental therapeutics 1999;289(1):371-7.
1999: Davide Verotta
A general solution for nonparametric control of a linear system using computer-controlled infusion pumps.
IEEE transactions on bio-medical engineering 1999;46(1):44-50.
1998: Davide Verotta
Characterizing the variability of system kernel and input estimates.
Annals of biomedical engineering 1998;26(5):870-82.
1998: K Park; Davide Verotta; S K Gupta; Lewis B Sheiner
Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile.
Journal of pharmacokinetics and biopharmaceutics 1998;26(4):471-92.
1998: Jean-Michel Gries; Neal L Benowitz; Davide Verotta
Importance of chronopharmacokinetics in design and evaluation of transdermal drug delivery systems.
The Journal of pharmacology and experimental therapeutics 1998;285(2):457-63.
1998: K Park; Davide Verotta; S K Gupta; Lewis B Sheiner
Passive versus electrotransport-facilitated transdermal absorption of ketorolac.
Clinical pharmacology and therapeutics 1998;63(3):303-15.
1997: G F Vanhove; Jean-Michel Gries; Davide Verotta; Lewis B Sheiner; R Coombs; Ann C Collier; Terrence F Blaschke
Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.
Antimicrobial agents and chemotherapy 1997;41(11):2433-8.
1997: G F Vanhove; H Kastrissios; Jean-Michel Gries; Davide Verotta; K Park; Ann C Collier; K Squires; Lewis B Sheiner; Terrence F Blaschke
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
Antimicrobial agents and chemotherapy 1997;41(11):2428-32.
1997: K Park; Davide Verotta; Terrence F Blaschke; Lewis B Sheiner
A semiparametric method for describing noisy population pharmacokinetic data.
Journal of pharmacokinetics and biopharmaceutics 1997;25(5):615-42.
1997: Davide Verotta
A general framework for non-parametric subject-specific and population deconvolution methods for in vivo-in vitro correlation.
Advances in experimental medicine and biology 1997;423():43-52.
1997: Jean-Michel Gries; I F Troconiz; Davide Verotta; M Jacobson; Lewis B Sheiner
A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex.
Clinical pharmacology and therapeutics 1997;61(1):70-82.
1996: K E Fattinger; Davide Verotta; HC Porchet; Alain Munafo; J Y Le Cotonnec; Lewis B Sheiner
Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide.
The American journal of physiology 1996;271(4 Pt 1):E775-87.
1996: Jean-Michel Gries; Neal L Benowitz; Davide Verotta
Chronopharmacokinetics of nicotine.
Clinical pharmacology and therapeutics 1996;60(4):385-95.
1996: G Stanley; Davide Verotta; N Craft; R A Siegel; J B Schwartz
Age and autonomic effects on interrelationships between lung volume and heart rate.
The American journal of physiology 1996;270(5 Pt 2):H1833-40.
1996: Jean-Michel Gries; R Upton; Y F Huang; Davide Verotta
A descriptive tool to characterize nonlinear kinetics, with applications to meperidine and lidocaine.
Journal of pharmaceutical sciences 1996;85(4):362-8.
1996: Davide Verotta
Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems.
Critical reviews in biomedical engineering 1996;24(2-3):73-139.
1995: K E Fattinger; Davide Verotta
A nonparametric subject-specific population method for deconvolution: II. External validation.
Journal of pharmacokinetics and biopharmaceutics 1995;23(6):611-34.
1995: K E Fattinger; Davide Verotta
A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples.
Journal of pharmacokinetics and biopharmaceutics 1995;23(6):581-610.
1995: K E Fattinger; Lewis B Sheiner; Davide Verotta
A new method to explore the distribution of interindividual random effects in non-linear mixed effects models.
Biometrics 1995;51(4):1236-51.
1995: K E Fattinger; Davide Verotta
Estimating bioavailability when clearance changes in time: the effect of model misspecification.
Clinical pharmacology and therapeutics 1995;58(5):595-600.
1995: Davide Verotta; Lewis B Sheiner
A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.
Journal of pharmacokinetics and biopharmaceutics 1995;23(1):1-4.
1994: I F Troconiz; Lewis B Sheiner; Davide Verotta
Semiparametric models for antagonistic drug interactions.
Journal of applied physiology (Bethesda, Md. : 1985) 1994;76(5):2224-33.
1993: Davide Verotta
Estimation and model selection in constrained deconvolution.
Annals of biomedical engineering 1993;21(6):605-20.
1993: Davide Verotta
Two constrained deconvolution methods using spline functions.
Journal of pharmacokinetics and biopharmaceutics 1993;21(5):609-36.
1993: J B Schwartz; I F Troconiz; Davide Verotta; S Liu; H Capili
Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil.
The Journal of pharmacology and experimental therapeutics 1993;265(2):690-8.
1992: J W Mandema; Davide Verotta; Lewis B Sheiner
Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.
Journal of pharmacokinetics and biopharmaceutics 1992;20(5):511-28.
1991: Davide Verotta; Lewis B Sheiner
Semiparametric analysis of non-steady-state pharmacodynamic data.
Journal of pharmacokinetics and biopharmaceutics 1991;19(6):691-712.
1991: Davide Verotta; J Kitts; R Rodriguez; J Coldwell; R D Miller; Lewis B Sheiner
Reversal of neuromuscular blockade in humans by neostigmine and edrophonium: a mathematical model.
Journal of pharmacokinetics and biopharmaceutics 1991;19(6):713-29.
1991: Davide Verotta; Lewis B Sheiner; S L Beal
Mean time parameters for generalized physiological flow models (semihomogeneous linear systems).
Journal of pharmacokinetics and biopharmaceutics 1991;19(3):319-31.
1990: Davide Verotta
An application of the D-optimal criterion to define the experimental design for a particular class of semi-parametric models.
Computer methods and programs in biomedicine 1990;33(3):181-7.
1990: Davide Verotta
Comments on two recent deconvolution methods.
Journal of pharmacokinetics and biopharmaceutics 1990;18(5):483-9; discussion 489-99.
1989: J B Schwartz; Davide Verotta; Lewis B Sheiner
Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions.
The Journal of pharmacology and experimental therapeutics 1989;251(3):1032-8.
1989: R A Boyd; S K Chin; O Don-Pedro; Davide Verotta; Lewis B Sheiner; Roger L Williams; Kathleen M Giacomini
The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose.
Clinical pharmacology and therapeutics 1989;46(4):408-19.
1989: Davide Verotta; Lewis B Sheiner; W F Ebling; D R Stanski
A semiparametric approach to physiological flow models.
Journal of pharmacokinetics and biopharmaceutics 1989;17(4):463-91.
1989: Davide Verotta; S L Beal; Lewis B Sheiner
Semiparametric approach to pharmacokinetic-pharmacodynamic data.
The American journal of physiology 1989;256(4 Pt 2):R1005-10.
1989: Davide Verotta
An inequality-constrained least-squares deconvolution method.
Journal of pharmacokinetics and biopharmaceutics 1989;17(2):269-89.
1987: Davide Verotta; Lewis B Sheiner
Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm.
Computer applications in the biosciences : CABIOS 1987;3(4):345-9.